

BARD1 CHANGES ITS NAME TO INOVIQ

- **Change of company name to INOVIQ Ltd**
- **New code ASX:IIQ from 9 December 2021**
- **INOVIQ represents 'intelligent innovation' as the Company builds an innovative portfolio of diagnostic and exosome-based products**

Melbourne, Australia, 8 December 2021: BARD1 Life Sciences Limited (ASX:BD1) (**BARD1** or the **Company**) is pleased to announce that following shareholder approval at its AGM on 29 November 2021, the Company's name has changed from BARD1 to INOVIQ Ltd (**INOVIQ**) and the ASX listing code will change from ASX:BD1 to **ASX:IIQ**. Investors are advised to update the Company's code to ASX:IIQ in watchlists and stock apps on 9 December 2021 when these changes will be implemented by the ASX.

The change of company name to INOVIQ better reflects the strategic vision, broader intellectual property assets and expanded product portfolio of the Company since its acquisition of Sienna Cancer Diagnostics Ltd in July 2020. The name BARD1 was linked to the BARD1 technology acquired in June 2016 and no longer reflects the Company's broader interests across its BARD1, SubB2M, NETs and hTERT technologies.

CEO Dr Leeearne Hinch said: "The name change to INOVIQ represents the evolution of the Company's expanded focus on developing and commercialising innovative diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The new name future-proofs the continued growth and expansion of our business, capabilities, and product portfolio. We thank shareholders for their support of the name change and look forward to unveiling the new brand and website in coming weeks."

Authorised by the Company Secretary, Tony Di Pietro.

- ENDS -

CONTACTS

Dr Leeearne Hinch
CEO
E leeearne@bard1.com
M +61 400 414 416

Dr Geoff Cumming
Non-executive Chairman
E geoff.cumming@bard1.com
M +61 417 203 021

Jane Lowe
IR Department
E jane.lowe@irdepartment.com.au
M +61 411 117 774

ABOUT INOVIQ LTD (From 9 December 2021)

INOVIQ Ltd (ASX:IIQ) (**INOVIQ**) is developing and commercialising an innovative portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The Company has commercialised the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Our cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers.

FORWARD LOOKING STATEMENTS

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may', 'should', 'expect', 'anticipate', 'estimate', 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.